Cancer centers and other hospitals, reeling from the loss of discounts and rebates on three widely used cancer drugs, are seeking to persuade drug maker Genentech to reverse its decision to channel these medications through six specialty distributors.
The Cancer Letter asked Patrick Loehrer, director of the Indiana University Melvin & Bren Simon Cancer Center, to discuss his institution's decision to close its 10-year-old proton beam center.
At its opening a decade ago, the Indiana University Health Proton Therapy Center was one of four such facilities in the U.S.
LISA RICHARDSON was named director of the CDC Division of Cancer Prevention and Control.
MARTINE EXTERMANN received the 2014 Paul Calabresi Award from the International Society of Geriatric Oncology. Extermann is the senior member of the Senior Adult Oncology and Health Outcomes & Behavior Programs at Moffitt Cancer Center.
MILAN MRKSICH was appointed associate director for research technology and infrastructure at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
MYRIAD GENETICS Inc. established a Tumor BRACAnalysis CDx laboratory in Munich.
THE NATIONAL COMPREHENSIVE CANCER NETWORK approved the VeriStrat predictive proteomics test for inclusion in its Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancer. The test is developed by Biodesix Inc.
FDA granted accelerated approval for Keytruda (pembrolizumab) for unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
